During this mission, the team will grow Janus base nanotubes that carry interleukin-12. Interleukin-12 is a protein already ...

T helper 17 (Th17) cells generate the pro-inflammatory cytokine interleukin-17 (IL17/IL17A). IL17 has been a target for a variety of therapeutic monoclonal antibodies and inhibitors to treat ...

Interleukin 2 (IL-2) is the only systemic treatment currently available that is capable of curing patients with metastatic renal cell cancer (RCC). The first indications that IL-2 could mediate ...

Summary: Tocilizumab is a novel monoclonal antibody that competitively inhibits the binding of interleukin-6 (IL-6) to its receptor (IL-6R). Inhibiting the entire receptor complex prevents IL-6 ...

Adults and adolescents treated with icotrokinra experienced improvements in their moderate to severe plaque psoriasis, ...

The American Academy of Dermatology annual meeting was packed with “massive advancements” across the field, Joel M. Gelfand, ...

In Europe, these therapies were introduced between 2006 and 2013. The anti-TNF era was followed by the emergence of interleukin (IL) inhibitors, with J&J’s Stelara (ustekinumab) leading the way ...

The FDA has accepted for review the BLA for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps.

Multiple myeloma (MM) is a blood cancer that affects plasma cells in bone marrow. It’s a particularly insidious form of ...

In this randomized, placebo-controlled replicate trial, depemokimab decreased the annual rate of exacerbations among patients ...